ported within 7-days follow-up, only 2 patients in each group developed a mild hematoma on vascular access site. There was no difference in all-cause mortality rate between both groups at 1-year follow-up (0.23%, 1 patient vs 1.21%, 7 patients, respectively; p=0,084).
Conclusions:
The PI value is an independent predictor of bleeding while on treatment with a P2Y12 receptor inhibitor following PCI for ACS. BARC 2 to 5 bleeding is significantly associated with an increase in the risk of death.
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Revascularization strategy and long-term outcomes in patients with a first episode of high-risk acute coronary syndrome 
Conclusions:
In patients with HRACS and multivessel CAD, the complete Rev had better prognosis than incomplete in the short and long-term. The complete Rev in one-vessel and multivessel disease had a similar benefit. The mode of complete Rev in multivessel disease showed a similar effect on long-term prognosis. Purpose: Contrast-induced acute kidney injury (CI-AKI) is a serious complication after percutaneous coronary intervention (PCI). CI-AKI has been associated with high in-hospital mortality and poor long-term survival. Pre-existing renal insufficiency is the strongest predictor for developing CI-AKI after PCI. However, in acute coronary syndrome (ACS) patients with normal renal function, risk factors for CI-AKI and its long term implications have not been well studied, and constitutes the aim of this study.
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Methods:
We performed a single-center observational study with prospective follow-up of 477 consecutive patients (mean age 65.2±12, 92 women [19.3%]) admitted with ACS undergoing PCI and with preexisting normal renal function (creatinine < 1.3 mg/dl), from October 2007 to April 2011. All patients undergoing PCI at our institution were prospectively followed a minimum of 12 months (mean 26.5±14.2 months). CI-AKI was defined as an increase in serum creatinine ≥ 0.5 mg/dl or ≥ 25 percent above baseline. (Figure 1 ). Conclusions: Our large-cohort retrospective study suggests that elevated CRP at PPCI is associated with significantly higher long-term mortality. Further work is required on strategies to modify inflammatory response following STEMI and improve clinical outcomes following PPCI. Purpose: Cilostazol, a phosphodiesterase III inhibitor, have been used for adjunctive dual anti-platelet therapy (DAT) after Percutaneous Coronary Intervention (PCI). The elevation of cAMP by cilostazol might lead to tachyarrhythmia. However, its clinical implications have never been investigated. Methods: The pilot study included 174 patients undergoing elective PCI in a prospective and randomized design. Patients were allocated in a 1:1 ratio to the Triple Anti-platelet Therapy (TAT, cilostazol and DAT) or the DAT. At baseline and at 6-month, 24-h holter was measured. Primary end-points were heart rate (HR) and number of ventricular premature capture (VPC) and secondary end-points were numbers of non-sustained ventricular tachycardia (NS-VT), atrial premature capture (APC), and Supraventricular Tachycardia (SVT). Results: 84 were allocated to the DAT group and the remaining 92 were allocated to the TAT group after elective PCI. Clinical and 24-h holter baseline was similar between the 2 groups. However, after follow-up of 6-month, HR and number of VPC in the TAT group higher than those of DAT group (HR, 68.9±9.3 bpm vs. 74.1±11.7 bpm, p = 0.005 and VPC, 79.7±201.0 vs. 510.8±1618.8, p < 0.001). There were no significant differences in the numbers of NS-VT, APC, and SVT between the 2 groups. Conclusions: TAT after PCI increased HR and number of VPC, compared with DAT. In patients with tachycardia and frequent VPC, the use of cilostazol, as an add-on to the DAT, should be more cautious.
P4794 | BEDSIDE
Randomized prospective impact of cilostazol associated with arrhythmia after percutaneous coronary intervention
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Peri-intervention averaged glycemia is a strong short-term predictor and glycated hemoglobin a long-term predictor for MACE after primary PCI Background: Diabetes mellitus (DM) is associated with worse clinical outcome in patients with STEMI treated with primary PCI (PPCI), however, few detailed data are available. Aim. To determine the correlation of the metabolic variables (periintervention averaged glycemia and glycated hemoglobin -HbA1c) with MACE in patients who had PPCI. Methods: 387 (42%) patients, from 919 consecutive STEMI treated with PPCI, had significant glycemic disorders: 206 (22%) type 2 DM and 181 (20%) impaired glucose tolerance. 3 groups were defined: group I of 217 (56%) patients with HbA1c<7% (good metabolic control); group II of 93 (24%) patients with HbA1c 7-8% (borderline); group III of 77 (20%) patients with HbA1c>8% (inadequate metabolic control). Primary outcome was MACE, defined as: death, myocardial infarction, stroke, and driven angina repeat revascularization, at 30 days and 1 year. Results: There were no differences in baseline characteristics between the 3 groups, apart from age (lower in group I) and baseline estimated GFR (by MDRD2 equation) (lower in group III). At 30 days, MACE was not different between groups (table); peri-intervention averaged glycemia >180 mg/dl predicted MACE, independent of HbA1c (r 2 =0.48; p<0.02). At 1 year, MACE was significantly lower in group I than in group III (p=0.025); death and myocardial infarction were also lower in group I and II than in group III (p<0.01); HbA1c was an independent predictor for MACE (r 2 =0.51; p<0.02), whereas peri-intervention averaged glycemia was not a predictor. Aims: The risk of contrast induced nephropathy (CIN) is predicted by the already proposed formula of the ratio of contrast volume to glomerular filtration rate (GFR). Recent data from literature undescore that the incidence of CIN is significantly influenced by admission glycemia. Therefore, our aim was to identify a predictive model of CIN based on the quantity of contrast used during pPCI, known independent predictors of CIN, and pre procedural glycemia. Methods and results: 679 STEMI patients treated with primary PCI (pPCI) were enrolled in our prospective study. CIN was defined as an absolute serum creatinine increase ≥0.3 mg/dl after procedure. Admission hyperglycemia was defined as glucose levels >198 mg/dl. Medium volume of contrast (CV) we used ranged
